Precigen has been granted a patent for methods and compositions involving antigen-binding polypeptides with increased expression on a cell surface and improved antigen-binding efficiency. The patent specifically focuses on chimeric antigen receptors (CARs) with a unique structure comprising an antigen-binding region, a transmembrane region, and a spacer region with a stalk region and one to five stalk extension regions. GlobalData’s report on Precigen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Precigen, Cancer treatment biomarkers was a key innovation area identified from patents. Precigen's grant share as of September 2023 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
A patent granted for chimeric polypeptides with improved antigen-binding
A recently granted patent (Publication Number: US11771718B2) describes a chimeric polypeptide that has potential applications in the field of immunotherapy. The chimeric polypeptide consists of an antigen-binding region, a transmembrane region, and a spacer region that connects the transmembrane region with the antigen-binding region. The spacer region includes a stalk region with a dimerization site and one to five stalk extension regions, each containing fewer dimerization sites than the stalk region.
The patent claims that at least one stalk extension region may have an amino acid sequence that is at least 80% identical to the amino acid sequence of the stalk region. The stalk region can be positioned either proximal or distal to the transmembrane region. The chimeric polypeptide is designed to exhibit increased expression on the surface of cells compared to a similar polypeptide without the stalk extension region.
The stalk extension regions may lack a dimerization site and typically consist of about 20 to 60 amino acids. Additionally, the stalk region may have a sequence with at least 80% identity to a CD8alpha hinge domain, a CD28 hinge domain, and/or a CTLA-4 hinge domain.
The antigen-binding region of the chimeric polypeptide can bind to various epitopes on proteins such as CD19, BCMA, CD44, a-Folate receptor, CAIX, CD30, ROR1, CEA, EGP-2, EGP-40, HER2, HER3, Folate-binding Protein, GD2, GD3, IL-13R-a2, KDR, EDB-F, mesothelin, CD22, EGFR, Folate receptor a, Mucins, MUC-1, MUC-16, GPC3, CSPG4, HER1/HER3, HER2, CD44v6, CD44v7/v8, CD20, CD174, CD138, L1-CAM, FAP, c-MET, PSCA, CS1, CD38, IL-11Ra, EphA2, CLL-1, MAGE-A1, h5T4, PSMA, TAG-72, EGFR, CD20, EGFRvIII, CD123, and/or VEGF-R2.
The chimeric polypeptide can be used to create modified immune effector cells, such as CAR-T cells, which have improved cytotoxicity compared to cells expressing a similar polypeptide without the stalk extension region. The modified immune effector cells may also express a cytokine, such as a membrane-bound IL15, and a cell tag, such as a truncated epidermal growth factor receptor.
The patent also includes a method for increasing the expansion of engineered T cells expressing the chimeric polypeptide by engineering the nucleic acid encoding the polypeptide to include a stalk extension domain.
Overall, this patent describes a novel chimeric polypeptide and its potential applications in immunotherapy, particularly in the development of modified immune effector cells with improved cytotoxicity.
To know more about GlobalData’s detailed insights on Precigen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
